on DBV TECHNOLOGIES (EPA:DBV)
DBV Technologies at the Citizens JMP Life Sciences Conference
On May 5, 2025, DBV Technologies announced its participation in the Citizens JMP Life Sciences Conference. Daniel Tassé, CEO, will speak at a fireside chat on May 7 in New York City. This session will be streamed live and accessible on the company's website, with a replay available for 90 days.
DBV Technologies, listed on Euronext and Nasdaq, is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies, particularly with its VIASKIN® technology and epicutaneous immunotherapy. The VIASKIN® patch aims to desensitize patients to allergens.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all DBV TECHNOLOGIES news